Fixed|Duration Ibrutinib plus Venetoclax Regimen Promising as First ...

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL

Treatment was administered in 28-day cycles. After completion of the FD regimen, patients who subsequently had confirmed progressive disease (PD) ...

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL

In summary, first-line ibrutinib plus venetoclax is an all-oral, once-daily, chemotherapy-free FD regimen that drives deep, durable responses and can be ...

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL

Results from the cohort investigating fixed-duration (FD) treatment with ibrutinib plus venetoclax are reported. Patients received 3 cycles of ...

Fixed-Duration Ibrutinib plus Venetoclax Regimen Promising as First ...

The randomized phase 2 CAPTIVATE clinical trial showed that first-line therapy with ibrutinib (Imbruvica) and venetoclax (Venclexta) for a fixed duration ...

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic ...

The 1-year DFS rate of 95% in placebo-randomly assigned patients with Confirmed uMRD suggests the potential for fixed-duration treatment with this all-oral, ...

Updated Phase 2 CAPTIVATE study results demonstrate sustained ...

Of the 61 patients with progressive disease after completion of FD I+V, 32 initiated subsequent treatment with single-agent ibrutinib (n=25) or ...

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL

First-line ibrutinib plus venetoclax represents the first all-oral, once-daily, chemotherapy-free, fixed-duration regimen for CLL. Abstract. CAPTIVATE ...

Ibrutinib and venetoclax in combination for chronic lymphocytic ...

In summary, the administration of 24 cycles of fixed-duration ibrutinib and venetoclax demonstrated its efficacy, characterized by a high rate of uMRD and a ...

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Three-year progression-free survival was 90.5% in the venetoclax–obinutuzumab–ibrutinib group and 75.5% in the chemoimmunotherapy group (hazard ...

Promising Data in CLL With Ibrutinib/Venetoclax Doublet

Further, findings from the phase 3 GLOW study (NCT03462719)2 showed that patients who received fixed duration ibrutinib plus venetoclax had ...

Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic ...

Ibrutinib- and venetoclax-based regimens (including the fixed-duration regimen of venetoclax plus obinutuzumab) have both demonstrated PFS benefit over ...

Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment ...

At 2 years of treatment with ibrutinib plus venetoclax, 111 patients (42.7%) stopped the regimen according to the MRD stopping rules. At 3 years ...

Ibrutinib Plus Venetoclax at a Fixed Duration Yields Positive PFS in ...

Ibrutinib plus venetoclax given at a fixed duration yielded favorable progression-free survival in patients with previously untreated, ...

4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.

Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from ...

Fixed-Duration Ibrutinib Plus Venetoclax Demonstrates Efficacy in ...

Ibrutinib- and venetoclax-based regimens have demonstrated a PFS benefit over chemoimmunotherapy in patients with previously untreated CLL and ...

Ibrutinib Plus Venetoclax for First-line Treatment of Chronic ...

With venetoclax-based combination therapies, an important issue is the optimal duration of therapy. In the present trial, patients received 24 ...

Time-Limited Ibrutinib Plus Venetoclax for CLL

A combination of ibrutinib plus venetoclax is a very effective first-line treatment for CLL, and 90% of patients are progression-free after ...

Articles Fixed-duration ibrutinib–venetoclax versus chlorambucil ...

In the GLOW study, fixed-duration ibrutinib–venetoclax showed superior progression-free survival versus chlorambucil–obinutuzumab in patients with previously ...

Fixed-Duration Ibrutinib Plus Venetoclax Hits Multiple Efficacy End ...

The combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) administered for a fixed duration elicited durable responses and sustained ...

Fixed-duration Ibrutinib Plus Venetoclax May Benefit Patients with ...

While the trial results suggested that fixed-duration ibrutinib plus venetoclax may be a beneficial first-line treatment for CLL, the benefit of ...